Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance

Abstract Objective The DUALIS study showed that switching to boosted darunavir (bDRV) plus dolutegravir (DTG; 2DR) was non-inferior to continuous bDRV plus 2 nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs; 3DR) in treatment-experienced virologically suppressed people living with HIV (...

Full description

Bibliographic Details
Main Authors: Eva Wolf, Christoph Boesecke, Annamaria Balogh, Helen Bidner, Christiane Cordes, Hans Heiken, Ivanka Krznaric, Tim Kümmerle, Hans-Jürgen Stellbrink, Jochen Schneider, Christoph D. Spinner, the DUALIS Study Group
Format: Article
Language:English
Published: BMC 2021-09-01
Series:AIDS Research and Therapy
Subjects:
Dolutegravir
Darunavir
HIV drug resistance
Integrase inhibitors
Protease inhibitors
Online Access:https://doi.org/10.1186/s12981-021-00384-6

Internet

https://doi.org/10.1186/s12981-021-00384-6

Similar Items